Kobayashi Y, Nagata M, Yamamoto H, Sakamoto Y
Second Department of Internal Medicine, Saitama Medical School.
Arerugi. 2000 Jul;49(7):600-3.
Suplatast tosilate has been shown to inhibit generation of Th2-type cytokines in vitro and used in the treatment of allergic diseases. Although the exact mechanism remains unknown, this compound attenuates the eosinophil infiltration in the asthmatic airway. In the present study, we examined whether suplatast tosilate directly modulates eosinophil migration in response to inflammatory mediators in vitro. Suplatast did not modify the spontaneous migration of eosinophils. On the other hand, eosinophil migration in response to PAF (1 microM) was significantly inhibited by 1 microM suplatast. Similarly, IL-5 (100 pM)-induced eosinophil migration was inhibited by 1 microM suplatast. These results suggest that suplatast tosilate inhibits eosinophil locomotion in response to PAF or IL-5 and thereby attenuates infiltration of the cells in allergic inflammation.
托西酸舒普拉泰已被证明在体外可抑制Th2型细胞因子的产生,并用于治疗过敏性疾病。尽管确切机制尚不清楚,但该化合物可减轻哮喘气道中的嗜酸性粒细胞浸润。在本研究中,我们检测了托西酸舒普拉泰是否能在体外直接调节嗜酸性粒细胞对炎症介质的迁移反应。舒普拉泰未改变嗜酸性粒细胞的自发迁移。另一方面,1 μM舒普拉泰可显著抑制嗜酸性粒细胞对PAF(1 μM)的迁移反应。同样,1 μM舒普拉泰可抑制IL-5(100 pM)诱导的嗜酸性粒细胞迁移。这些结果表明,托西酸舒普拉泰可抑制嗜酸性粒细胞对PAF或IL-5的运动反应,从而减轻细胞在过敏性炎症中的浸润。